[{"orgOrder":0,"company":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Hematology","graph2":"Phase IV","graph3":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Benefic\u00eancia Portuguesa de S\u00e3o Paulo \/ Merck & Co"},{"orgOrder":0,"company":"University of Queensland","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"University of Queensland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"University of Queensland \/ Merck & Co","highestDevelopmentStatusID":"10","companyTruncated":"University of Queensland \/ Merck & Co"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Hematology","graph2":"Phase IV","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamad Medical Corporation \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"Hamad Medical Corporation \/ Merck & Co"},{"orgOrder":0,"company":"Sunshine Coast Hospital and Health Service","sponsor":"The Prince Charles Hospital | Mater","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Sunshine Coast Hospital and Health Service","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunshine Coast Hospital and Health Service \/ The Prince Charles Hospital | Mater","highestDevelopmentStatusID":"11","companyTruncated":"Sunshine Coast Hospital and Health Service \/ The Prince Charles Hospital | Mater"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ceftolozane Sulfate","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Weill Medical College of Cornell University \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Weill Medical College of Cornell University \/ Merck & Co"}]

Find Clinical Drug Pipeline Developments & Deals for Ceftolozane Sulfate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Beneficência Portuguesa de São Paulo

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Beneficência Portuguesa de São Paulo

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 02, 2024

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Sunshine Coast Hospital and Health Service

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Sunshine Coast Hospital and Health Service

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 13, 2023

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase IV

                          Sponsor : The Prince Charles Hospital | Mater

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Hamad Medical Corporation

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Hamad Medical Corporation

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 29, 2021

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Weill Medical College of Cornell University

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Weill Medical College of Cornell University

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 17, 2020

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          University of Queensland

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          University of Queensland

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 23, 2020

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 10, 2020

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 05, 2019

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          MD Anderson Cancer Center

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          MD Anderson Cancer Center

                          Country arrow
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 03, 2018

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Merck & Co | National Cancer Institute

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 26, 2017

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 13, 2017

                          Lead Product(s) : Ceftolozane Sulfate

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank